Gaël S. Roth

1.2k total citations
46 papers, 524 citations indexed

About

Gaël S. Roth is a scholar working on Oncology, Molecular Biology and Hepatology. According to data from OpenAlex, Gaël S. Roth has authored 46 papers receiving a total of 524 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 17 papers in Molecular Biology and 13 papers in Hepatology. Recurrent topics in Gaël S. Roth's work include Pancreatic and Hepatic Oncology Research (15 papers), Cancer Mechanisms and Therapy (11 papers) and Hepatocellular Carcinoma Treatment and Prognosis (10 papers). Gaël S. Roth is often cited by papers focused on Pancreatic and Hepatic Oncology Research (15 papers), Cancer Mechanisms and Therapy (11 papers) and Hepatocellular Carcinoma Treatment and Prognosis (10 papers). Gaël S. Roth collaborates with scholars based in France, United States and Spain. Gaël S. Roth's co-authors include Thomas Decaens, Zuzana Macek Jílková, Julien Ghelfi, Patrice N. Marche, Hervé Lerat, Giovanni Abbadessa, Nicolas Reynoird, Christian Sengel, Keerthi Kurma and Arnaud Seigneurin and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Gaël S. Roth

41 papers receiving 519 citations

Peers

Countries citing papers authored by Gaël S. Roth

Since Specialization

Citations

This map shows the geographic impact of Gaël S. Roth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gaël S. Roth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gaël S. Roth more than expected).

Fields of papers citing papers by Gaël S. Roth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gaël S. Roth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gaël S. Roth. The network helps show where Gaël S. Roth may publish in the future.

Co-authorship network of co-authors of Gaël S. Roth

This figure shows the co-authorship network connecting the top 25 collaborators of Gaël S. Roth. A scholar is included among the top collaborators of Gaël S. Roth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gaël S. Roth. Gaël S. Roth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1532TiP Zolbetuximab with gemcitabine + nab-paclitaxel (GN) in first-line treatment of Claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized study 2024 ·Annals of Oncology ·Won Park, Eileen M. O’Reilly, Li Cp, D-Y. Oh, (unknown), Gaël S. Roth, Takahiro Nakajima, Diarmuid Moran, Jianfeng Yang, (unknown), (unknown)	1
2	Completion pancreatectomy during pancreatoduodenectomy: A lifesaving solution in high‐risk patients 2024 ·World Journal of Surgery ·(unknown), Édouard Girard, (unknown), J. Abba, (unknown), Cécile Betry, Olivier Risse, Gaël S. Roth, (unknown), Mircea Chirica	0
3	A simple prognostic score to predict recurrence after pancreaticoduodenectomy for ampullary carcinoma: results from the French prospective FFCD-AC cohort 2024 ·ESMO Open ·Gaël S. Roth, Anna Pellat, Guillaume Piessen, Karine Le Malicot, (unknown), (unknown), David Tougeron, Vincent Hautefeuille, Marine Jary, (unknown), Morgane Amil, (unknown), Marie Müller, Thierry Lecomte, Marielle Guillet, (unknown), Claire Genet, (unknown), Olivier Bouché, Julien Taı̈eb	0
4	Tumor-associated macrophages confer resistance to chemotherapy (Trifluridine/Tipiracil) in digestive cancers by overexpressing thymidine phosphorylase 2024 ·Cancer Letters ·(unknown), Marie‐Hélène Laverrière, Maxime Henry, (unknown), (unknown), Cécile Arellano, (unknown), Fabienne Thomas, Véronique Josserand, Édouard Girard, Gaël S. Roth, Arnaud Millet	2
5	Metabolic reprogramming of hypoxic tumor-associated macrophages through CSF-1R targeting favors treatment efficiency in colorectal cancers 2024 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), (unknown), (unknown), Renata Grespan, Yoshiki Yamaryo‐Botté, Cyrille Y. Botté, Fabienne Thomas, Marie‐Hélène Laverrière, Édouard Girard, Gaël S. Roth, Arnaud Millet	7
6	1684TiP PARPiPANC: A multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer 2023 ·Annals of Oncology ·Philippe A. Cassier, Claire Cropet, Clélia Coutzac, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Marion Chauvenet, François Ghiringhelli, Gaël S. Roth, David Pérol	0
7	Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: What are the explanatory factors? 2023 ·British Journal of Clinical Pharmacology ·(unknown), Xavier Fonrose, Fabienne Thomas, Gaël S. Roth, Emmanuelle Jacquet, (unknown), (unknown), (unknown), (unknown), Françoise Stanke‐Labesque, Elodie Gautier‐Veyret	5
8	Ezurpimtrostat, A Palmitoyl-Protein Thioesterase-1 Inhibitor, Combined with PD-1 Inhibition Provides CD8+ Lymphocyte Repopulation in Hepatocellular Carcinoma 2023 ·Targeted Oncology ·Eloïne Bestion, (unknown), Annemilaï Tijeras‐Raballand, Gaël S. Roth, Thomas Decaens, (unknown), Soraya Mezouar, Éric Raymond, Philippe Halfon	11
9	LBA77 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD 2023 ·Annals of Oncology ·Aziz Zaanan, Olivier Bouché, Christelle de la Fouchardière, (unknown), Karine Le Malicot, Simon Pernot, Pascal Artru, (unknown), Kaïs Aldabbagh, F. Khemissa Akouz, H. Castanie, (unknown), Damien Botsen, Marie Müller, Gaël S. Roth, Thierry Lecomte, Jean–Marc Phelip, Côme Lepage, Christophe Louvet	8
10	Radiological diagnosis of hepatocellular carcinoma does not preclude biopsy before treatment 2023 ·JHEP Reports ·(unknown), (unknown), (unknown), Gaël S. Roth, Nathalie Stürm, Matthieu Roustit, Alexandre Bône, Julien Ghelfi, Charlotte Costentin, Thomas Decaens	6
11	SMYD3 Impedes Small Cell Lung Cancer Sensitivity to Alkylation Damage through RNF113A Methylation–Phosphorylation Cross-talk 2022 ·Cancer Discovery ·(unknown), Simone Hausmann, Gaël S. Roth, Clément Oyeniran, Tanveer Ahmad, (unknown), Joshua R. Brickner, (unknown), Florent Chuffart, (unknown), (unknown), (unknown), Marianne Tardif, Pascal W.T.C. Jansen, Yohann Couté, Michiel Vermeulen, Pierre Hainaut, Paweł K. Mazur, Nima Mosammaparast, Nicolas Reynoird	18
12	First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers 2022 ·Liver Cancer ·James J. Harding, Ahmad Awada, Gaël S. Roth, Thomas Decaens, Philippe Merle, Nuria Kotecki, Chantal Dreyer, (unknown), (unknown), Soraya Mezouar, (unknown), Eloïne Bestion, Valérie Paradis, Philippe Halfon, Ghassan K. Abou‐Alfa, Éric Raymond	16
13	Safety and Efficacy of Transarterial Chemoembolization in Elderly Patients with Intermediate Hepatocellular Carcinoma 2022 ·Cancers ·Gaël S. Roth, Olivier Hernandez, (unknown), (unknown), (unknown), Julien Ghelfi, (unknown), Christian Sengel, Ivan Bricault, Thomas Decaens, Charlotte Costentin	3
14	Structural and Socio-Spatial Determinants Influencing Care and Survival of Patients with a Pancreatic Adenocarcinoma: Results of the PANDAURA Cohort 2022 ·Cancers ·Gaël S. Roth, Yohan Fayet, (unknown), Françoise Ducimetière, (unknown), Claire Cropet, Sylvie Chabaud, Anne-Marie Marion-Audibert, (unknown), Thomas Walter, Mustapha Adham, Mathieu Baconnier, (unknown), Nicolas Williet, Pascal Artru, (unknown), Isabelle Ray‐Coquard, Fadila Farsi, (unknown), Christelle de la Fouchardière	1
15	Endovascular Lymphatic Decompression via Thoracic Duct Stent Placement for Refractory Ascites in Patients with Cirrhosis: A Pilot Study 2022 ·Journal of Vascular and Interventional Radiology ·Julien Ghelfi, (unknown), (unknown), Christian Sengel, (unknown), Édouard Girard, Gaël S. Roth, Alexandre Bellier, Ivan Bricault, Thomas Decaens	8
16	Les macrophages associés à la tumeur 2022 ·médecine/sciences ·(unknown), (unknown), Marie‐Hélène Laverrière, Thomas Decaens, Gaël S. Roth, Arnaud Millet	1
17	Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment 2021 ·International Journal of Molecular Sciences ·(unknown), Gaël S. Roth, Thomas Decaens, Patrice N. Marche, Hervé Lerat, Zuzana Macek Jílková	36
18	Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma 2017 ·Molecular Cancer Therapeutics ·Gaël S. Roth, Zuzana Macek Jílková, (unknown), Keerthi Kurma, (unknown), Giovanni Abbadessa, (unknown), Benoît Busser, Patrice N. Marche, Vincent Leroy, Thomas Decaens	23
19	Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives 2017 ·European Journal of Cancer ·Gaël S. Roth, Thomas Decaens	53
20	Performance of bile aspiration plus brushing to diagnose malignant biliary strictures during endoscopic retrograde cholangiopancreatography 2016 ·SHILAP Revista de lepidopterología ·Gaël S. Roth, Philippe Bichard, (unknown), Hubert Roth, Jean Auroux, Olivier Risse, Christian Létoublon, (unknown), Ivan Bricault, Vincent Leroy, Thomas Decaens	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact